Latest News
Inhibrx Biosciences, Inc.
- Inhibrx Biosciences introduces Phase 2 ozekibart study results for conventional chondrosarcoma at MSTS 2026
- CEO Mark Lappe buys 10,040 shares in Inhibrx Biosciences stock
- Form 4 Inhibrx Biosciences Inc: Mark Lappe (Director, CEO) For: 14 October
- Learn Why The Bull Case For Inhibrx Biosciences Stock Could Change Following Conference Data Presentations
- Two CEO-linked trusts buy 10,040 Inhibrx Biosciences (INBX) shares; no trading plan is reported.
- Inhibrx Announces Participation in Upcoming Scientific Conferences
- Cancer-study presentations from Inhibrx will take place in Madrid, Miami and Seoul.
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
- Inhibrx Biosciences (INBX) Shares Moved, What Is Driving Attention Now?
- Inhibrx Biosciences stock reports stronger cancer study data
Headlines from the last 30 days, linking to the original publishers. See all market news →